

## Re: Your request made under the Freedom of Information Act 2000

**Our pharmacy system doesn't store diagnosis data, so we're unable to determine this against the prescribed treatment. To ascertain this data, the Trust would need to perform an audit of each individual patient record, which wouldn't be achievable within the s.12 timescale of the Freedom of Information Act 2000.**

Q1. In the past 3 months (or the latest 3 months data you have available), how many melanoma patients were treated with:

- Bevacizumab (Avastin)
- Dacarbazine (DTIC)
- Trametinib (Mekinist)
- Dabrafenib (Tafinlar)
- Ipilimumab (Yervoy)
- Vemurafenib (Zelboraf)
- Nivolumab (Opdivo)
- Nivolumab + Ipilimumab (Opdivo + Yervoy)
- Pembrolizumab (Keytruda)
- Vemurafenib + cobimetinib (Zelboraf + Cotellic)
- Dabrafenib + Trametinib (Tafinlar + Mekinist)
- Braftovi (encorafenib) in combination with Mektovi (binimetinib) for BRAF V600 patients
- Other active systemic anti-cancer therapy [please state]
- Palliative care only

Q2. In the past 3 months (or the latest 3 months data you have available), how many metastatic melanoma patients were treated with the following:

- Ipilimumab

Our Ref: 137/2022

JANUARY 2022

- Ipilimumab AND Nivolumab
- Nivolumab
- Pembrolizumab
- Dabrafenib AND Trametinib
- Any Other Targeted Therapy (Dabrafenib /Encorafenib AND Binimetinib /Trametinib /Vemurafenib /Vemurafenib AND Cobimetinib)
- Other active systemic anti-cancer therapy
- Palliative care only